Fate Therapeutics (FATE) FCF Margin (2012 - 2026)

Fate Therapeutics (FATE) has 14 years of FCF Margin data on file, last reported at 2391.15% in Q1 2026.

• Quarterly FCF Margin fell 27549.0% year-over-year to 2391.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1719.98% (down 78924.0% YoY) and the FY2025 annual result came in at 1685.78%, down 78332.0% from the prior year.
• FCF Margin slipped to 2391.15% in Q1 2026, from 2108.77% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 54.37% in Q1 2023 to a low of 3289.6% in Q2 2023.
• A 5-year average of 1342.37% and a median of 1365.82% in 2025 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2023 — FCF Margin slumped 291225 bps — and 2024, when it surged 281073 bps.
• Tracing FATE's FCF Margin over 5 years: stood at 107.21% in 2022, then tumbled by 2272 bps to 2543.08% in 2023, then soared by 41 bps to 1501.24% in 2024, then sank by 40 bps to 2108.77% in 2025, then retreated by 13 bps to 2391.15% in 2026.
• The last three FCF Margin figures came in at 2391.15% (Q1 2026), 2108.77% (Q4 2025), and 1365.82% (Q3 2025), per Business Quant data.